Total knee arthroplasty (TKA) is widely accepted as an effective procedure to relieve joint pain, increase mobility, and improve quality of life for patients with end-stage osteoarthritis of the knee.1) However, postoperative pain following TKA that is not well controlled may hamper patients from early rehabilitation and rapid recovery and increase length of hospital stay. Such patients may also ex-
perience complications such as lung atelectasis and venous thromboembolism. Furthermore, severe postoperative pain might influence perioperative blood loss through various mechanisms such as sympathetic stimulation and increased arterial blood pressure. The excruciating postoperative pain might also increase stress on the cardiovascular system and be related to ischemic cardiac events and myocardium insufficiency.

For contemporary TKA, the multimodal pain management including neuroaxial anesthesia, periarticular injection (PAI) and/or peripheral nerve block, and opioid-sparing analgesia with multidrug regimen could be effective to control pain by avoiding side effects of high-dose single analgesia. Nonsteroidal anti-inflammatory drugs (NSAIDs) have become one of the widely used agents to relieve moderate to severe pain and to reduce inflammation after orthopedic surgery. A recent randomized controlled trial (RCT) and meta-analysis demonstrated that NSAIDs administration could significantly mitigate pain intensity and opioid consumption, as well as opioid-related adverse events, after TKA. Furthermore, some investigators reported that NSAIDs yielded equivalent analgesic effect to peripheral nerve block in TKA.

Although effective in controlling pain and inflammation, NSAIDs are associated with a serious risk of gastrointestinal, renal, and cardiovascular adverse events. Currently, a selective cyclooxygenase-2 (COX-2) inhibitor, which reduces the risk of peptic ulceration and platelet inhibition, has been considered by some surgeons, including authors of the present study, as a good alternative agent for opioid-sparing strategy, particularly in elderly patients who underwent TKA. However, the COX-2 inhibitor is not devoid of adverse effects entirely and their use should still be avoided for patients who have renal impairment and risk of a thromboembolic event. Even though these patients might be assumed to eventually have worse pain experience, there was sparse evidence demonstrating any exact outcome and a possible need for auxiliary pain control. Therefore, we conducted the present study to assess perioperative outcomes including pain level, recovery, blood loss, and complications of patients who underwent TKA and who were not candidates for additional NSAIDs in their multimodal pain control regimen.

**METHODS**

We conducted a retrospective investigation into patients diagnosed with primary osteoarthritis of the knee and underwent primary unilateral TKA. The patients who had a previous history of knee surgery, prior knee infection, and had been diagnosed with secondary osteoarthritis were excluded. The patients were divided into two groups. The control group received 40 mg of parenteral parecoxib (Dynastat, Pfizer, New York, NY, USA) every 12 hours during the first 48 hours after TKA and continued with celecoxib 200 mg twice a day until discharge to home. The second group, the No-NSAIDs group, did not receive NSAIDs during the postoperative period because of having had a diagnosis of chronic kidney disease stage ≥ 3 or preoperative serum creatinine (sCr) > 1.2, allergy to NSAIDs or sulfonamides, previous history of peptic ulceration or hemorrhage, or a cardiovascular and cerebrovascular event. Using propensity score matching, patients who underwent TKA without NSAIDs use (No-NSAIDs group) were matched 1 : 1 with the control group. The study was approved by the Institutional Review Board of Naresuan University (IRB No. P3-0016/2563).

All surgical procedures were performed by a single surgeon alone (AL) using an identical preoperative protocol and surgical technique. Aspirin therapy was discontinued at least 7 days before surgery. Premedication (gabapentin and anxiolytic drug) on the night before the surgery was applied for all cases. All procedures were carried out under regional anesthesia with bupivacaine (0.5% Marcaine, AstraZeneca, Sweden). A standard medial parapatellar arthrotomy with approximately 10 cm of skin incision was performed with tourniquet control at 250 mmHg. The bone cut was prepared with a conventional instrument by using intramedullary and extramedullary reference guides for the distal femur and the proximal tibia, respectively. The opening of the femoral medullary canal was occluded with a bone plug after finishing the femoral bone preparation. The patella was selectively re surfaced. A PAI was performed in all cases with 20 mL bupivacaine that was diluted with normal saline solution to a total volume of 75 mL. Posterior-stabilized, fixed-bearing knee prostheses were implanted with bone cement in all patients. Topical tranexamic acid was poured into the knee joint before the arthrotomy closure. A vacuum drain and compressive dressing were also applied and subsequently removed 24 hours after the surgery.

Similar postoperative care was utilized for all patients. The intravenous patient-controlled analgesia (PCA) was set to inject an on-demand bolus of 0.5 mg of morphine sulphate with a 5-minute lockout period, and the amount of morphine consumption was recorded. Acetaminophen (500 mg) was administered orally after the surgery and then every 8 hours during hospitalization. After 48 hours, the PCA, antibiotics, and all catheters were discarded. Then, 2 mg of morphine was given intravenous-
ly every 8 hours and additional 2 mg of morphine was applied as rescue analgesia every 4 hours during the patient’s stay in the hospital. Postoperative pain level was assessed with a 10-cm visual analog scale (VAS) at 6, 12, 18, 24, 48, 72, and 96 hours after surgery. An identical postoperative physiotherapy protocol was conducted, a continuous passive motion device was applied, and progress was recorded daily. Chemoprophylaxis for deep vein thrombosis (DVT), consisting of low-molecular-weight heparin injection and bridging oral warfarin, was administered for all patients.

Blood tests including complete blood count, sCr, and cardiac troponin-T (cTnT) level were routinely performed preoperatively and then at 24 hours, 48 hours, and 72 hours after TKA. Outcome measurements for this study were postoperative VAS score, amount of morphine consumption, knee flexion angle, drain output, calculated blood loss (CBL), blood transfusion rate, and length of stay (LOS). Any complications that happened during the course of the study were also recorded. To identify patients having acute kidney disease, we compared the highest postoperative sCr obtained within 72 hours after TKA to preoperative sCr values. According to the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease criteria, (1) at-risk of acute kidney injury was defined as 1.5 × rising in sCr, (2) acute kidney injury was defined as 2 × rising in sCr, and (3) acute kidney failure was defined as 3 × rising in sCr.  

The cTnT level > 14 ng/L was positive for myocardial infarction in our laboratory system. All outcomes were prospectively recorded.

For men, TBV (mL) = (0.0003669 × height $^3$ [cm]) + (32.19 × body weight [kg]) + 604

For women, TBV (mL) = (0.0003561 × height $^3$ [cm]) + (33.08 × body weight [kg]) + 183

CBL (mL) = TBV [mL] × (Hb$_i$ – Hb$_e$)/Hb$_i$ + sum of blood products transfused [mL],

where Hb$_i$ [g/dL] was defined as the preoperative Hb and Hb$_e$ [g/dL] was the postoperative Hb. The difference between preoperative and 48-hour postoperative Hb was applied with the Hb balance method to determine CBL. Allogeneic blood was transfused if the Hb level was below 9.0 g/dL as our institutional cutoff values.

### Statistical Analysis

Propensity score incorporating demographic data that included age, sex, body mass index, American Society of Anesthesiologists (ASA) class, and level of preoperative Hb (Hb $\geq$ 12 for female and $\geq$ 13 for male vs. Hb < 12 for female and < 13 for male) were used to match the studied group with the control group. All measured characteristics and outcomes were summarized with descriptive statistics including mean and standard deviation (SD). All outcomes

### Table 1. Demographic Data of the Control and No-NSAIDs Groups before and after Propensity Score Matching

| Variable                  | Control (n = 80) | No-NSAIDs (n = 54) | p-value | Control (n = 52) | No-NSAIDs (n = 52) | p-value |
|----------------------------|-----------------|--------------------|---------|-----------------|--------------------|---------|
| Age (yr)                   | 66.32 ± 8.16    | 68.09 ± 7.74       | 0.210   | 66.37 ± 8.11    | 67.79 ± 7.6        | 0.358   |
| Sex                        |                 |                    |         |                 |                    |         |
| Female                     | 60 (75)         | 50 (92.6)          | 0.011*  | 51 (98.1)       | 49 (94.2)          | 0.618   |
| Male                       | 20 (25)         | 4 (7.4)            | 0.011*  | 1 (1.9)         | 3 (5.8)            | 0.618   |
| Body mass index (kg/m$^2$) | 27.44 ± 3.68    | 27.03 ± 3.4        | 0.517   | 27.57 ± 3.69    | 27.05 ± 3.43       | 0.453   |
| ASA class                  |                 |                    |         |                 |                    |         |
| 1                          | 4 (5)           | 0                  | 0.148   | 0               | 0                  | NA      |
| 2                          | 48 (60)         | 22 (40.7)          | 0.035*  | 31 (59.6)       | 22 (42.3)          | 0.116   |
| 3                          | 28 (35)         | 32 (59.3)          | 0.008*  | 21 (40.4)       | 30 (57.7)          | 0.116   |
| Preoperative Hb (g/dL)     | 12.49 ± 1.33    | 12.03 ± 1.01       | 0.028*  | 12.1 ± 1.18     | 12.02 ± 1.02       | 0.722   |

Values are presented as mean ± standard deviation or number (%).
NSAID: nonsteroidal anti-inflammatory drug, ASA: American Society of Anesthesiologists, NA: not available, Hb: hemoglobin.
*Statistically significant (p < 0.05).
were compared between groups using an independent t-test and Fisher’s exact test for continuous and categorical variables, respectively. The sample size of 52 patients in each group would have 86.4% power to detect a difference of 1.5 of VAS for pain score with SD of 2.5, with type I error of 5%. Stata/MP 15.0 software (StataCorp., College Station, TX, USA) was used for all statistical analysis. Statistical significance was defined as $p < 0.05$.

RESULTS

The 134 participating patients were divided into two groups, 80 patients were in the control group, while 54 patients were in the No-NSAIDs group. After propensity score match, there were 52 patients in each group with comparable demographic data as shown in Table 1. The preoperative VAS score, range of knee motion, Hb, cTnT, and TBV were not significantly different between groups, but the baseline sCr of No-NSAIDs group was significantly higher than that of the control group (Table 2).

The VAS pain scores of the No-NSAIDs group were significantly higher than those of the control group during the entire postoperative period (Fig. 1). The No-NSAIDs group also had significantly higher cumulative morphine consumption at 24 hours and 48 hours after the surgery than the control group. The knee flexion angle of the control group was higher than that of the No-NSAIDs group and the difference was statistically significant at 48 hours postoperatively. The No-NSAIDs group had more postoperative nausea vomiting (PONV) and longer LOS than the control group, but the difference did not reach a level of statistical significance (Table 3). The CBL was 552.52 mL (interquartile range [IQR], 403.83–710.64) for the No-NSAIDs group and 397.65 mL (IQR, 266.72–622.87) for the control group ($p = 0.02$). However, the blood transfusion rate was not different between the No-NSAIDs group and control group (23.1% and 17.3%, respectively, $p = 0.63$). The drain output of the No-NSAIDs group was also significantly greater than that of the control group (Table 3).

The sCr of the No-NSAIDs group was continuously higher than that of the control group up until 72 hours after the surgery, but no patient experienced sCr elevating beyond 1.5× of baseline in both groups. The cTnT of the No-NSAIDs group was rising during the first 48 hours and significantly higher than that of the control group at 48 hours (Table 4). Each group had 2 patients with cTnT exceeding 14 ng/L during the first 72 hours postoperatively and these patients had no subsequent symptom and sign of cardiovascular event during hospitalization. Until the last follow-up, there was 1 periprosthetic fracture of

![Fig. 1. Pain intensity measured by visual analog scale (VAS) at 6–96 hours after total knee arthroplasty. There was significant difference during the entire postoperative period ($p \leq 0.01$). NSAID: nonsteroidal anti-inflammatory drug.](image)

| Table 2. Preoperative Characteristics and Blood Tests of the Control and No-NSAIDs Groups after Propensity Score Matching |
|---------------------------------------------------------------|
| Characteristic | Control (n = 52) | No-NSAIDs (n = 52) | $p$-value |
|-----------------|------------------|------------------|----------|
| VAS pain score  | 6.43 ± 2.30      | 6.31 ± 2.39      | 0.418    |
| ROM (°)         | 106 ± 15.37      | 100.39 ± 23.97   | 0.305    |
| Hemoglobin (g/dL)| 12.1 ± 1.18      | 12.02 ± 1.02     | 0.722    |
| Serum creatinine (mg/dL) | 0.8 ± 0.23 | 0.95 ± 0.31 | 0.010* |
| cTnT (ng/L)    | 9.85 ± 8.85      | 10.71 ± 7.46     | 0.595    |
| TBV (mL)       | 3,733.03 ± 449.30| 3,616.19 ± 495.73| 0.211    |

Values are presented as mean ± standard deviation.

NSAID: nonsteroidal anti-inflammatory drug, VAS: visual analog scale, ROM: range of motion, cTnT: cardiac troponin-T, TBV: total blood volume.

*Statistically significant ($p < 0.05$).
the distal femur in the control group. For the No-NSAIDs group, 1 patient developed DVT and was treated with anticoagulant, 1 required readmission due to wound oozing related to warfarin, and 1 had cerebrovascular disease with hemiparesis.

### DISCUSSION

In this study, we found that the No-NSAIDs group had significantly higher VAS scores at any time point and consumed significantly more morphine in the first 48 hours postoperatively than the control group. The No-NSAIDs group tended to have a lower degree of knee flexion angle, a higher rate of PONV, and longer LOS than the control group. These results accord with the meta-analysis conducted by Du and Gu\(^6\) and the RCT by Zhu et al.,\(^7\) who reported that the patients who were postoperatively administered parenteral parecoxib had significantly less opioid use, lower pain scores, and better range of knee motion after TKA. Hence, patients who were not candidates for

---

**Table 3. Perioperative and Postoperative Outcomes of the Control and No-NSAIDs Groups after Propensity Score Matching**

| Variable                  | Control            | No-NSAIDs          | p-value |
|---------------------------|--------------------|--------------------|---------|
| Operative time (min)      | 63.65 ± 15.59      | 60.74 ± 6.00       | 0.226   |
| Drain output (mL)         | 199.78 ± 101.29    | 269.38 ± 140.31    | 0.007*  |
| Knee flexion angle (°)    |                    |                    |         |
| 24 hr                     | 54.73 ± 18.57      | 50.1 ± 23.83       | 0.288   |
| 48 hr                     | 73.43 ± 18.17      | 65.26 ± 21.71      | 0.045*  |
| 72 hr                     | 84.5 ± 11.89       | 80.15 ± 18.79      | 0.180   |
| 96 hr                     | 90.2 ± 12.76       | 88.52 ± 10.49      | 0.534   |
| Morphine PCA (mg)         |                    |                    |         |
| 24 hr                     | 9.01 ± 8.39        | 15.84 ± 10.27      | 0.002*  |
| 48 hr                     | 12.6 ± 11.34       | 25.36 ± 16.68      | <0.001* |
| PONV (%)                  | 0.48 ± 1.02        | 0.67 ± 1.19        | 0.405   |
| LOS (day)                 | 5.16 ± 1.08        | 5.58 ± 1.67        | 0.134   |

Values are presented as mean ± standard deviation. NSAID: nonsteroidal anti-inflammatory drug, PCA: patient-controlled analgesia, PONV: postoperative nausea vomiting, LOS: length of stay. *Statistically significant (p < 0.05).

**Table 4. Postoperative cTnT and sCr of the Control and No-NSAID Groups after Propensity Score Matching**

| Variable                  | Control            | No-NSAIDs          | p-value |
|---------------------------|--------------------|--------------------|---------|
| cTnT (ng/L)               | 9.85 ± 8.85        | 10.71 ± 7.46       | 0.595   |
| 24 hr                     | 12.05 ± 19.49      | 13.26 ± 9.79       | 0.710   |
| 48 hr                     | 10.89 ± 10.41      | 17.7 ± 20.13       | 0.044*  |
| 72 hr                     | 11.32 ± 9.17       | 13.32 ± 8.26       | 0.446   |
| sCr (mg/dL)               |                    |                    |         |
| 24 hr                     | 0.74 ± 0.21        | 0.88 ± 0.24        | 0.004*  |
| 48 hr                     | 0.74 ± 0.18        | 0.89 ± 0.26        | 0.003*  |
| 72 hr                     | 0.8 ± 0.23         | 0.89 ± 0.28        | 0.211   |

Values are presented as mean ± standard deviation. cTnT: cardiac troponin-T, sCr: serum creatinine, NSAID: nonsteroidal anti-inflammatory drug. *Statistically significant (p < 0.05).
NSAIDs might benefit from additional analgesic modalities to better control their pain and enhance recovery. Currently, corticosteroid and acetaminophen are considered as useful supplements for controlling post-TKA pain. Intravenous acetaminophen has been revealed by meta-analysis as an efficacious adjunct to multimodal analgesia after total joint arthroplasty in terms of pain scores and opioid consumption in the first 72 hours.13) Tammachote and Kanitnate14) also revealed that administration of 0.15 mg/kg of intravenous dexamethasone can significantly relieve pain between 12 hours to 21 hours after TKA and reduce rates of PONV and level of C-reactive protein compared with placebo, but might be associated with transient hyperglycemia. On the other hand, the efficacy of PAI might also be improved by some strategies such as location of injection15) or adding some adjuvants to the PAI mixture.8,16) Alternatively, additional peripheral nerve block could also be considered as an analgesic supplement to overwhelm the pain after TKA.17-20)

Our second finding was the coincidence of higher pain intensity and blood loss in the No-NSAIDs group than in the control group, even if the blood transfusion rate was not different. The cTnT of No-NSAIDs group was rising during the first 48 hours after TKA and reached a statistically significant difference from the control group at 48 hours. Some patients in both groups had postoperative cTnT exceeding 14 ng/L in the first 72 hours after the surgery, but all did not have a cardiovascular event. In a previous study, Guay21) found a positive correlation between morphine consumption and postoperative blood loss by some mechanisms. They conjectured that postoperative pain increased blood loss through sympathetic stimulation and increased arterial blood pressure. Despite the pain not being severe enough to increase the systemic arterial blood pressure, pain rising while patient doing physiotherapy might induce muscle contraction, high venous blood pressure, and then increased blood loss of that limb. In addition, Mangano et al.19) reported that pain, fluid shift, temperature changes, impaired pulmonary gas exchange, and sleep deprivation could alter myocardial oxygen demand and precipitate ischemia. They also revealed that postoperative pain was one of the factors that could alter the use of oxygen in the myocardium and induce myocardial ischemia during the first 48 hours after cardiac and non-cardiac surgery. Nevertheless, Kim et al.21) revealed a contrary result as pain had no effect on postoperative blood pressure and blood loss even after bilateral TKA. Other research, however, found that perioperative blood loss had an effect on neither postoperative pain nor opioid use.22,23)

In conclusion, patients who were not candidates for NSAIDs administration had significantly higher pain scores and consumed significantly more morphine after TKA. They also tended to have greater blood loss and the rising of cardiac biomarkers during the first 48 hours after the surgery. Hence, these patients may benefit from supplementary analgesia and appropriate perioperative monitoring.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENTS**

We thank Mr. Roy I. Morien of the Naresuan University Graduate School for his assistance in editing the English
expression and grammar in this document. We also thank Pariphat Chompoonutprapa, MD, Watcharapong Eiamjumras, MD, Thanawat Tantimethanon, MD, Passakorn Teekaweerakit, MD for their technical assistance.

Orcid
Artit Laoruengthana
https://orcid.org/0000-0001-5827-6411

Nattharut Chaibuddanugul
https://orcid.org/0000-0002-4070-6230

Piti Rattanaprichavej
https://orcid.org/0000-0002-2802-0762

Saran Malisorn
https://orcid.org/0000-0001-6139-9340

Piroon Tangsripong
https://orcid.org/0000-0002-7662-3541

Krit Pongpirul
https://orcid.org/0000-0003-3818-9761

References

1. Choi YJ, Ra HJ. Patient satisfaction after total knee arthroplasty. Knee Surg Relat Res. 2016;28(1):1-15.

2. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116(2):248-73.

3. Guay J. Postoperative pain significantly influences postoperative blood loss in patients undergoing total knee replacement. Pain Med. 2006;7(6):476-82.

4. Mangano DT, Wong MG, London MJ, Tubau JF, Rapp JA. Perioperative myocardial ischemia in patients undergoing noncardiac surgery II: incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group. J Am Coll Cardiol. 1991;17(4):851-7.

5. Korean Knee Society. Guidelines for the management of postoperative pain after total knee arthroplasty. Knee Surg Relat Res. 2012;24(4):201-7.

6. Du X, Gu J. The efficacy and safety of parecoxib for reducing pain and opioid consumption following total knee arthroplasty: a meta-analysis of randomized controlled trials. Int J Surg. 2018;59:67-74.

7. Zhu Y, Wang S, Wu H, Wu Y. Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study. Eur J Orthop Surg Traumatol. 2014;24(3):395-401.

8. Tammachote N, Kanitnate S, Manuwong S, Panichkul P. Periarticular multimodal drug injection is better than single anesthetic drug in controlling pain after total knee arthroplasty. Eur J Orthop Surg Traumatol. 2018;28(4):667-75.

9. Tonnisrin N, Chalacheewa T, Saipimpong S, Tran D, Finlayson RJ. Parenteral parecoxib provides a similar reduction in opioid requirement to single-shot sciatic nerve block after total knee arthroplasty when combined with continuous femoral nerve block. J Med Assoc Thai. 2017;100(1):57-63.

10. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8-14.

11. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-32.

12. Chen JY, Chin PL, Moo IH, et al. Intravenous versus intraarticular tranexamic acid in total knee arthroplasty: a double-blinded randomised controlled noninferiority trial. Knee. 2016;23(1):152-6.

13. Liang L, Cai Y, Li A, Ma C. The efficiency of intravenous acetaminophen for pain control following total knee and hip arthroplasty: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(46):e8586.

14. Tammachote N, Kanitnate S. Intravenous dexamethasone injection reduces pain from 12 to 21 hours after total knee arthroplasty: a double-blind, randomized, placebo-controlled trial. J Arthroplasty. 2020;35(2):394-400.

15. Laoruengthana A, Rattanaprichavej P, Rasamimongkol S, Galassi M. Anterior vs posterior periarticular multimodal drug injections: a randomized, controlled trial in simultaneous bilateral total knee arthroplasty. J Arthroplasty. 2017;32(7):2100-4.

16. Tsukada S, Wakui M, Hoshino A. The impact of including corticosteroid in a periarticular injection for pain control after total knee arthroplasty: a double-blind randomised controlled trial. Bone Joint J. 2016;98(2):194-200.

17. Kositanurit I, Toolyodpun S, Podjanasupawun S, Rasamimongkol S, Weerakul S, Laoruengthana A. Does preemptive femoral nerve block provide additional pain relief for periarticular injection in total knee arthroplasty? J Med Assoc Thai. 2018;101(3):243.

18. Youm YS, Cho SD, Cho HY, Hwang CH, Jung SH, Kim KH. Preemptive femoral nerve block could reduce the rebound pain after periarticular injection in total knee arthroplasty. J Arthroplasty. 2016;31(8):1722-6.
19. Green E, Frane N, Ganz M, Stockton R, Stapleton E, Mallen J. Additive effect of continuous adductor canal block and liposomal bupivacaine periarticular injection in total knee arthroplasty. Eur J Orthop Surg Traumatol. 2019;29(7):1525-32.

20. Kampitak W, Tanavalee A, Ngarmukos S, Amarase C. Opioid-sparing analgesia and enhanced recovery after total knee arthroplasty using combined triple nerve blocks with local infiltration analgesia. J Arthroplasty. 2019;34(2):295-302.

21. Kim SY, An YJ, Kim SH, Kim HK, Park JS, Shin YS. The effect of postoperative pain on postoperative blood loss after sequential bilateral total knee arthroplasty. Korean J Anesthesiol. 2011;60(2):98-102.

22. Hegarty P, O'Brien S, Stevenson M, Beverland D. The effect of peri-operative blood loss on postoperative pain following total knee arthroplasty. J Orthop. 2015;12(3):147-50.

23. Laoruengthana A, Rattanaprichavej P, Rasamimongkol S, Galassi M, Weerakul S, Pongpirul K. Intra-articular tranexamic acid mitigates blood loss and morphine use after total knee arthroplasty: a randomized controlled trial. J Arthroplasty. 2019;34(5):877-81.

24. Xie J, Ma J, Yao H, Yue C, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplasty. 2016;31(11):2458-64.

25. Barrington JW, Lovalet ST, Ong KL, Watson HN, Emerson RH Jr. Postoperative pain after primary total knee arthroplasty: comparison of local injection analgesic cocktails and the role of demographic and surgical factors. J Arthroplasty. 2016;31(9 Suppl):288-92.

26. Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop. 2007;31(1):39-44.

27. Laoruengthana A, Jarusriwanna A, Rattanaprichavej P, Rasamimongkol S, Varakornpipat P, Pongpirul K. Timing of periarticular injection has no effect on postoperative pain and functional recovery in simultaneous bilateral total knee arthroplasty: a prospective randomized, double-blinded trial. BMC Musculoskelet Disord. 2019;20(1):162.

28. Laoruengthana A, Rattanaprichavej P, Chaibhuddanugul N, Varakornpipat P, Galassi M, Pongpirul K. Blood loss reduction: effect of different knee prosthesis designs and use of tranexamic acid: a randomized controlled trial. Eur J Orthop Surg Traumatol. 2019;29(7):1519-24.

29. Rattanaprichavej P, Laoruengthana A, Rasamimogkol S, Varakornpipat P, Reosanguanwong K, Pongpirul K. The effect of prosthesis design on blood loss in simultaneous bilateral total knee arthroplasty: closed-box versus open-box prosthesis. Clin Orthop Surg. 2019;11(4):409-15.